Smith & Nephew’s Shares Rallied 5.16% on Q4 and FY23 Results

The Smith & Nephew plc (LON: SN) share price rallied 5.16% after its Q4 and FY 2023 trading results were released. The company’s fourth quarter showcased a revenue of $1,458 million, marking a 6.4% increase on an underlying basis from the previous year’s $1,365 million. The reported growth reached 6.8%, slightly boosted by a 0.4% foreign exchange tailwind.

The year concluded with revenues soaring to $5,549 million, a 7.2% rise on an underlying basis from $5,215 million in 2022, surpassing initial forecasts. The reported growth stood at 6.4% after adjusting for an 80 basis points foreign exchange headwind.

WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.

Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.

5.0

Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

Orthopaedics experienced a 5.7% growth, laying the groundwork for future advancements. Despite challenges in the Chinese market, the Sports Medicine & ENT sectors witnessed a 10% increase. Advanced Wound Management continued its growth trajectory with a 6.4% increase, sustaining its previous year’s momentum.

The company’s trading profit rose 7.6% to $970 million, with a trading profit margin of 17.5%, aligning with projections. The reported operating profit was $425 million, slightly down from $450 million in the prior year.

Operational cash flow improved significantly to $829 million, and the trading cash flow increased to $635 million. Earnings per share adjusted (EPSA) were 82.8 cents, with actual EPS at 30.2 cents. The full-year dividend remained stable at 37.5 cents per share.

Implementing a comprehensive 12-Point Plan is on course, showing promising signs of impacting financial results. The innovation-led strategy is fueling higher growth and has resulted in a robust pipeline of new products. The strategic acquisition of CartiHeal underscores the company’s leadership in the domain of Sports Medicine biological healing.

Despite challenges such as ongoing inflation, a 70 basis points impact from China’s Volume-Based Procurement (VBP) within Sports Medicine Joint Repair, and transactional foreign exchange issues, the company anticipates positive operating leverage and benefits from its 12-point Plan to offset these headwinds effectively.

For 2024, the company projects an underlying revenue growth of 5.0% to 6.0%, with a reported growth slightly lower at 4.6% to 5.6%. The trading profit margin is expected to reach or exceed 18.0%, with steady midterm targets.

Smith & Nephew (SN) share price.

The Smith & Nephew share price rallied 5.16% to trade at 1181.0p from Monday’s closing price of 1123.0p.